Savara announces participation in the h.c. wainwright & co. 3rd annual bioconnect investor conference

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the h.c. wainwright & co. 3rd annual bioconnect investor conference on may 20, 2025, at 4:30pm et/1:30pm pt. the live webcast and subsequent replay will be available on the “events & presentations” section of the company's corporate website and will.
SVRA Ratings Summary
SVRA Quant Ranking